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Pancreatic ductal adenocarcinoma (PDAC) is characterized by an extensive fibrotic reaction
or desmoplasia and complex involvement of the surrounding tumor microenvironment.
Pancreatic stellate cells are a key mediator of the pancreatic matrix and they promote
progression and invasion of pancreatic cancer by increasing cell proliferation and offer-
ing protection against therapeutic interventions. Our study utilizes human tumor-derived
pancreatic stellate cells (HTPSCs) isolated from fine needle aspirates of pancreatic cancer
tissue from patients with locally advanced, unresectable pancreatic adenocarcinoma before
and after treatment with full-dose gemcitabine plus concurrent hypo-fractionated stereo-
tactic radiosurgery. We show that HTPSCs survive in vivo chemotherapy and radiotherapy
treatment and display a more activated phenotype post-therapy. These data support the
idea that stellate cells play an essential role in supporting and promoting pancreatic cancer
and further research is needed to develop novel treatments targeting the pancreatic tumor
microenvironment.
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INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy
with poor prognosis (1). It is characterized by its rapid pro-
gression, early local invasion and metastasis, and poor response
to chemotherapy and radiotherapy (1–3). An extensive fibrotic
reaction or desmoplasia (4) and complex involvement of the sur-
rounding tumor microenvironment are common defining factors
of PDAC (5). The stromal compartment of the pancreas is com-
posed of extracellular matrix (ECM) proteins, pancreatic stellate
cells (PSCs), and immune cells. The exact mechanisms of involve-
ment of this tumor matrix are still being elucidated. However,
recent findings show that interactions between pancreatic can-
cer cells (PCCs), ECM proteins, and growth factors secreted by
stromal components activate intracellular signals that protect can-
cer cells from apoptosis (4). Furthermore, PSCs stimulate the
growth of PCCs by increasing tumor cell proliferation, promot-
ing epithelial–mesenchymal transition, enhancing metastasis, and
providing radioprotection to tumor cells (6–9).
Pancreatic stellate cells are myofibroblast-like cells found in the
stromal compartment of the pancreas in interlobular areas and in
interacinar regions (10). They have a flattened angular appear-
ance with elongated cytoplasmic processes on phase-contrast
microscopy and are characterized by the presence of numerous
lipid droplets in the cytoplasm containing auto-fluorescent vit-
amin A stored as retinyl palmitate. During pancreatic injury of
inflammation, PSCs transform from a quiescent state into an acti-
vated, myofibroblast-type phase. Studies in rodents and humans
have identified several cytokines, growth factors, and signaling
molecules as regulators of PSC activation (11–13). Morphologic,
molecular, and behavioral features and markers of PSC activation
have been identified as: increased cell migration and contraction,
enlarged nucleus, increased proliferation, and expression of inter-
mediate filament proteins vimentin, desmin, and glial fibrillary
acidic protein (GFAP) (10–12, 14–17). These markers, in addition
to the presence of intracellular lipid droplets, aid in distinguishing
activated PSCs from normal fibroblasts.
Emerging studies suggest that ablation of cancer stem cells
(CSCs) is of critical significance for effective treatment cancer
(18–20). Recent data suggest that PSCs may enhance the cancer
stem-like phenotype in PCCs (21–23). Hamada and colleagues
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show that indirect co-culture of PCCs with PSCs enhanced the
spheroid-forming ability of cancer cells and induced the expres-
sion of cancer stem cell-related genes ABCG2, Nestin, and LIN28
(21). In a complimentary study, Lonardo and group demonstrate
that PSCs are an important component of the tumor stroma for
creating a paracrine niche for pancreatic CSCs. In their model,
PSC-derived Nodal/Activin drove self-renewal and invasiveness of
pancreatic CSCs (22). These studies suggest that targeting PSCs
and other tumor microenvironment components can assist in dis-
rupting the cancer stem cell niche and should be considered as a
part of cancer stem cell treatment strategies.
Two reports have described the protective effect that PSCs
impart against chemotherapy and radiation on PCCs (6, 8). How-
ever, in vitro studies on human tumor-derived pancreatic stellate
cells (HTPSC) are limited (24) and little is known about the direct
effect that chemotherapy and radiation have on human PSCs (24,
25). Our study shows that human cancer-associated PSCs can be
isolated from fine needle aspirates (FNAs) of pancreatic cancer
tissue from patients with locally advanced, unresectable pancre-
atic adenocarcinoma before and after treatment with full-dose
gemcitabine plus concurrent hypo-fractionated stereotactic radio-
surgery (SRS) and maintained in primary culture for studies of
cell behavior. We isolated paired samples of HTPSCs before and
after treatment from FNAs of in situ tumors in patients enrolled
in a study assessing the utility of sequential tumor sampling for
assessing therapeutic response. Cells were placed into primary
cell culture and HTPSCs were identified by a combination of
in situ techniques and morphology. A novel single-cell tracking
software was utilized to characterize the behavior of the cultured
HTPSCs. Cell activation (motility, locomotion, membrane expan-
sion/contraction) was compared before and after combination
chemotherapy/radiation. HTPSCs showed evidence of increased
activation post-therapy with increased motility and locomotion
and greater ratios of membrane expansion and contraction as
compared to HTPSCs isolated from the same patient before treat-
ment. The findings are compatible with the notion that current
therapies targeting PCCs may not inactivate PSCs. Since it is pos-
sible that activated PSCs contribute to survival of PCCs being
targeted by the chemotherapy and radiation, treatments may need
to be broadened to include targeting of this cell type as well (23,
26–28). Further studies elucidating stellate-specific markers for
inactivation and their therapeutic targets may lead to novel com-
bination therapies directed to this significant component of the
pancreatic adenocarcinoma microenvironment.
MATERIALS AND METHODS
ETHIC STATEMENT
This study was approved by the Georgetown University Oncology
Institutional Review Board of Washington, DC, USA, and followed
the Ethical Principles for Medical Research Involving Human Sub-
jects from the Declaration of Helsinki. Written informed consent
was obtained from subjects.
CLINICAL TRIAL
Patients with previously untreated locally advanced, unresectable
pancreatic cancer were enrolled in a pilot study designed
to demonstrate the feasibility and safety of administering
FIGURE 1 |Treatment algorithm and tumor imaging and sampling
schedule. Patients with locally advanced, unresectable pancreatic
adenocarcinoma received full-dose gemcitabine (G) plus concurrent
hypo-fractionated stereotactic radiosurgery (SRS). Stereotactic radiosurgery
was administered on the off week of the first cycle of gemcitabine.
Restaging imaging was performed every 2 months. Endoscopic ultrasound
with fine needle aspiration (EUS-FNA) with fiducial placement was
performed prior to therapy and serial EUS-FNAs were performed after 2 and
6 months of therapy.
hypo-fractionated SRS concurrently with full-dose gemcitabine
(G). In an effort to decrease late duodenal toxicity, we exam-
ined the use of fractionated SBRT with full-dose gemcitabine (29).
Patients received gemcitabine (1000 mg/m2) on days 1, 8, and 15
of every 28-day cycle, for up to 6 months. Patients were also treated
with 5 Gy of SRS daily over five consecutive days (typically days
22–26) of Cycle 1 only. Patients also underwent serial endoscopic
ultrasound-guided fine needle aspiration (EUS-FNA) of pancre-
atic masses prior to therapy, after 2 months, and after 6 months
(Figure 1).
PRIMARY HUMAN PANCREATIC CELL CULTURE PROTOCOL
Primary cultures of HTPSCs were generated from EUS-FNA
aspirates obtained from patients with locally advanced, unre-
sectable pancreatic adenocarcinoma before treatment (Pre) and
at 6 months following treatment with gemcitabine (G) and SRS
(Post) (Figure 1). Immediately upon collection, FNAs were placed
in DMEM (high glucose) (Invitrogen, Carlsbad, CA, USA) with
1% fetal bovine serum (FBS), 10 mL/L of antibiotic–antimycotic
(Invitrogen, Carlsbad, CA, USA) and moved to a laminar flow tis-
sue culture hood in the laboratory. All subsequent manipulations
were performed using standard sterile tissue culture techniques.
After collection, 1 mL of dispase and 2 mL of Trypsin–EDTA were
added to the media and the tubes were incubated for 30 min
at 37°C with occasional vortexing. After incubation, the tissue
was further dissociated by triturating with a sterile pipette. The
pancreatic tumor cell suspensions were then subjected to gravity
centrifugation for 5 min at 1800 rpm. The pellets were resus-
pended in 5 mL of FCM Lysing Solution (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA) to lyse red blood cells and incubated
at room temperature for 5 min with occasional trituration with
sterile pipette. The pancreatic cell suspensions were again sub-
jected to gravity centrifugation for 5 min at 1800 rpm. After the
supernatant was removed, the pellets were resuspended in 2 mL
of complete media containing DMEM (high glucose), 10% FBS,
10 ng/mL epidermal growth factor (EGF), 100 U of human insulin
(per 500 mL of medium), and 10 mL/L of antibiotic–antimycotic.
The cultures were plated in a single well of a six-well tissue cul-
ture treated plate and placed securely on humidified incubation
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chamber of inverted Nikon Eclipse TE300/PerkinElmer Spinning
Disc Confocal microscope system (Waltham, MA, USA) at 37°C
with 5% CO2. Cells were allowed to attach for 24 h, wells were
gently washed of debris with media, and replaced with fresh com-
plete media previously equilibrated for CO2 in the incubator and
warmed at 37°C.
CELL IMAGING
Images were obtained with inverted Nikon Eclipse TE300/
PerkinElmer Spinning Disc Confocal microscope system
(Waltham, MA, USA) with humidified incubation chamber using
10× objective lens in phase-contrast mode and Volocity software
(v 5.3.1, PerkinElmer, Waltham, MA, USA) as previously described
(30). Briefly, three to five sets of 812µm× 875µm contiguous
fields were selected in a square (5× 5) configuration in the mid-
dle of each well depending on cellular location. A focus map was
created for each point and time-lapse image acquisition was set
in 15-min intervals. Cells were imaged for 3–7 days. One to two
milliliters of complete media were added daily.
IMMUNOHISTOCHEMISTRY
Immediately after time-lapse imaging, cells were prepared in the
respective well of a six-well plate and stained by immunofluo-
rescence with vimentin 1:50 (sc-7557; Santa Cruz Biotechnology,
Santa Cruz, CA, USA) and fluorescently labeled secondary anti-
body FITC anti-goat (sc-2024; Santa Cruz Biotechnology, Santa
Cruz,CA,USA). Sections (5 mm thick) of formalin-fixed,paraffin-
embedded pancreatic adenocarcinoma FNAs were prepared and
stained by immunohistochemical staining with GFAP (GA5) 1:50
(3670S; Cell Signaling, Danvers, MA, USA). Digital photographs
taken with Nikon Eclipse E800M microscope with DMX1200 soft-
ware; Nikon Instruments, Inc. (Melville, NY, USA) and Olympus
IX71 with Olympus DP Capture Software (Center Valley, PA,
USA).
For immunohistochemistry, heat induced epitope retrieval
(HIER) was performed by immersing the tissue sections at 98°C
for 20 min in 10 mM citrate buffer (pH 6.0) with 0.05% Tween.
Immunohistochemical staining was performed using a horserad-
ish peroxidase labeled polymer (K4001; Dako, Carpinteria, CA,
USA) according to manufacturer’s instructions. Briefly, slides were
treated with 3% hydrogen peroxide and 10% normal goat serum
for 10 min each, and exposed to primary antibody for GFAP (1:50,
3670; Cell Signaling, Danvers, MA, USA) for 1 h at room temper-
ature. Slides were exposed to anti-mouse labeled HRP for 30 min
and DAB chromagen (Dako, Carpinteria, CA, USA) for 5 min.
Slides were counterstained with Hematoxylin (Harris Modified
Hematoxylin; Fisher, Waltham, MA, USA) at a 1:17 dilution for
2 min at room temperature, blued in 1% ammonium hydroxide for
1 min at room temperature, dehydrated, and mounted with Acry-
mount (McKinney, TX, USA). Sections with the omitted primary
antibody were used as negative controls.
For immunofluorescence, cells in each well of a six-well plate
were fixed for 15 min in 4% formaldehyde, rinsed with PBS,
blocked for 20 min with 10% normal blocking serum, and incu-
bated with primary antibody for vimentin (1:50, sc-7557; Santa
Cruz Biotechnology, Santa Cruz, CA, USA) for 60 min at 37°C.
After washing, secondary antibody was applied for 45 min in a dark
chamber. After a final washing, wells were covered with anti-fade
reagent (#9071; Cell Signaling, Danvers, MA, USA) with DAPI
(#8961; Cell Signaling, Danvers, MA, USA).
CELL TRACKING
After 3–7 days of time-lapse image acquisition, Timm’s Tracking
Tool (TTT) (31, 32) was used to track individual cell migration
as previously described (30). Briefly, time-lapse images for each
point were loaded into TTT; individual human tumor-derived
pancreatic stellate cells (HTPSCs) were identified on the screen by
morphology (a flattened angular appearance and long cytoplas-
mic processes giving them a typical “stellate” appearance) and the
presence of multiple cytoplasmic lipid-droplet deposits. Each cell’s
trajectory through the time-lapse images was recorded in TTT by
following each cell’s nucleus.
CELL MOTILITY, SPEED, AND MEMBRANE EXPANSION/CONTRACTION
MEASUREMENTS
As described above, time-lapse images for each point were loaded
into TTT and individual HTPSCs were identified on the screen
by morphology and cytoplasmic lipid-droplet deposits. Total cell
distance traveled in the x,y axis was recorded via TTT tracking
(Figure 2A) and cell speed was calculated by s= d/t where d is
distance traveled and t is total time of travel. Additionally, each
change of direction event was recorded manually by graphing
the x,y coordinates of distance traveled and directional change
(Figure 2B). For each cell, the base diameter was measured in
pixels by recording the x,y coordinates of the cell boundary. The
total pixels were converted to micrometers (0.73µm/pixel). Cells
were observed in the time-lapse images and membrane expansion
and contraction events were noted whenever the cell membrane
expanded by greater than 50% of total body length. During each
membrane expansion, the x,y coordinates of the cell boundary
were recorded at the cell’s longest points (Figure 2C). If the cell was
diagonally positioned, the expansion length was calculated using
the Pythagorean theorem a2+ b2= c2, where c is cell diameter
(Figure 2D). The expansion and contraction ratio was calculated
by x = b/e where b is the base cell diameter and e is the expanded
cell diameter.
STATISTICAL ANALYSIS
Differences and variance (σ) in mean cell speed, total distance trav-
eled, and expansion and contraction ratios were compared with
two-way ANOVA (GraphPad Prism version 6 for Mac, GraphPad
Software, La Jolla, CA, USA). Significance was assigned at p< 0.05;
n= 3 patients per cohort.
RESULTS
HUMAN TUMOR-DERIVED PANCREATIC STELLATE CELLS CAN BE
ISOLATED FROM FINE NEEDLE ASPIRATES AND MAINTAINED IN
CULTURE
Human tumor-derived pancreatic stellate cells were identifiable
by morphology in primary culture after 16–24 h of incubation
and formed small colonies after 48–72 h (Figure 3A). HTPSCs
were the predominant cell type identified during culture; the het-
erogeneous culture also included epithelial cells and non-stellate
fibroblasts. HTPSCs were initially characterized by a flattened
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FIGURE 2 | Cell motility, speed, and membrane expansion/contraction
parameters. (A)Time-lapse series of images showing multidirectional
migration of a representative human tumor-derived pancreatic stellate cell at
50-min intervals. (B) Representative cell path used to determine total
distance traveled by tracking individual cell nucleus in time-lapse
video-microscopy using TTT software. Circles represent the cell nucleus at
observed points when change of direction took place. Shaded circle
represents nucleus at time 0. Cell expansion and contraction were measured
by (C) calculating expanded cell diameter on x,y or (D) by calculating the
hypotenuse of the triangle (white line) representative of expanded cell after
obtaining x,y coordinates (m=minutes). Minutes represent elapsed time
after first observation in vitro. Scale bar: 50µm.
angular appearance, the presence of multiple cytoplasmic lipid
droplets, long cytoplasmic processes giving them a typical“stellate”
appearance, and cytoplasmic expansion and contraction behavior.
HTPSC isolation correlated with diagnostically adequate EUA-
FNA samples collected from patients with locally advanced, unre-
sectable pancreatic adenocarcinoma before treatment (pre) and
at 6 months following treatment with gemcitabine (G) and SRS
(post) (Figure 3B).
HUMAN TUMOR-DERIVED PANCREATIC STELLATE CELLS STAIN
POSITIVE FOR GFAP AND VIMENTIN
Pancreatic adenocarcinoma sections showed positive staining for
GFAP localized to stellate-shaped cells and their cytoplasmic
processes. These stellate-shaped cells were localized in the interaci-
nar space with cytoplasmic processes extending around the base of
adjacent acinar cells (Figure 4A). After 72 h in culture, cells stained
positive for vimentin showing a fibrillar staining pattern in the cell
cytoplasm and had the presence of auto-fluorescent lipid droplets
(Figure 4B). These markers of stellate cells were correlated with
the morphological characteristics we saw in culture of live cells: a
flattened angular appearance, the presence of multiple cytoplas-
mic lipid droplets, long cytoplasmic processes, and cytoplasmic
expansion and contraction behavior.
STELLATE CELL BEHAVIOR IS ALTERED IN SAMPLES ISOLATED FROM
PATIENTS TREATED WITH FULL-DOSE GEMCITABINE PLUS
CONCURRENT HYPO-FRACTIONATED SRS
To define the parameters of individual cell motility, we mea-
sured cell migration speed, total distance traveled, and expan-
sion/contraction ratios in HTPSCs isolated from FNAs of patients
with locally advanced, unresectable pancreatic adenocarcinoma.
Behaviors of individual cells isolated at baseline before treatment
(Pre) were compared to cells isolated at 6 months following treat-
ment with G+ SRS (Post) (Figures 4 and 5). Although the speed
of HTPSC migration was not significantly different in the pre-
treatment versus post-treatment samples (Figure 5A), the variance
of speed was greater in cells from the pre-treatment samples [21–
90µm/h (σ= 291)] compared to cells from the post-treatment
samples [24–60µm/h (σ= 99)] (ANOVA, p< 0.05) and the mean
total distance traveled was 1.9-fold greater in cells from post-
treatment samples (mean 198 SEM± 21 pre; mean 370 SEM± 33
post; ANOVA,p< 0.05). While pre-treatment cells traveled a max-
imum of 350µm, post-treatment cells traveled up to 597µm
over the same time frame (Figure 5B). Membrane extension was
measured by calculating expansion/contraction ratios. On aver-
age, cells pre-treatment extended 2× their body length compared
to a 2.8× extension in cells post-treatment, a 1.3-fold increase
(ANOVA, p< 0.05) (Figure 5C). The number of times these
expansion/contraction events took place was not different between
groups (Figure 5D).
DISCUSSION
The tumor microenvironment plays an important role in the initi-
ation, progression, and invasion of PDAC (5–7, 22, 33–35). Stellate
cells are one of the major mediators in the microenvironment of
the pancreas and are responsible for contributing to the malig-
nant phenotype of PCCs (6, 9). Furthermore, in vivo and in vitro
studies have shown that activated PSCs play a critical role in the
pathogenesis of pancreatic fibrosis (desmoplasia) and pancreati-
tis (15, 36, 37) (a risk factor for pancreatic cancer) (38). PSCs
are activated early during pancreatic injury as a result of necro-
sis and inflammation. Once activated, PSCs can regulate ECM
remodeling, contribute to inflammatory cytokine signaling, and
provide the major source of collagen. This excessive accumulation
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FIGURE 3 | Histology and morphology of human tumor-derived
pancreatic stellate cells. (A) Representative phase-contrast image of
human tumor-derived pancreatic stellate cells in monolayer after 72 h in
culture. EUS-FNAs were placed in standard cell culture conditions, resulting
in the outgrowth of myofibroblast-like cells. These stellate cells are
characterized by a flattened angular appearance, the presence of
cytoplasmic lipid droplets, long cytoplasmic processes giving them a typical
“stellate” appearance, and cytoplasmic expansion and contraction behavior.
(B) Representative hematoxylin/eosin (H&E) stained section and
phase-contrast bright field images from time-lapse movies of cell cultures
from patients with locally advanced, unresectable pancreatic
adenocarcinoma before treatment (pre) and at 6 months following
treatment with gemcitabine (G) and stereotactic radiosurgery (SRS) (post).
White arrowheads point to cytoplasmic lipid droplets; black arrows point to
lipid-droplet containing pancreatic stellate cells; white arrows point to other
non-stellate cells in culture; black arrowheads point to pancreatic ductal
adenocarcinoma cells. Scale bar: 50µm.
of ECM proteins leads to fibrosis and contributes to pancreatitis
(33, 34, 39).
The complexity of the pancreatic microenvironment and its
involvement in PDAC suggest that members of this matrix may
also mediate therapeutic response. Although radiation therapy
inhibits cell proliferation and induces apoptosis in many tumor
FIGURE 4 | Immunohistochemical staining of human tumor-derived
pancreatic stellate cells. (A) Representative sections of pancreatic
adenocarcinoma with positive staining of glial fibrillary acidic protein (GFAP)
(black arrows). Scale bar: 20µm. (B) Representative immunofluorescence
staining of human tumor-derived pancreatic stellate cells with positive
vimentin expression (FITC green) and auto-fluorescent cytoplasmic lipid
droplets (orange). Nuclei counterstained with DAPI.
cells, radiation has been shown to enhance pancreatic fibrosis in
PDAC (33). Additionally, data from in vitro and in vivo animal
studies show that PSCs mediate radioprotection of PCCs (8) and
impair tumor cell response to chemotherapy and radiation (6).
Importantly, recent publications have elucidated a role of PSCs
in enhancing the stem-like phenotype of pancreatic CSCs and in
driving self-renewal and invasiveness of pancreatic CSCs (21, 22).
The stromal component of PDAC, including PSCs has been shown
to support and protect PCCs from the deleterious effects of anti-
cancer agents (6, 8, 23, 40). When a stellate cell-targeting agent
was used in combination with chemotherapy, tissue delivery of
gemcitabine was enhanced and tissue metformin concentration
was doubled. Notably, the combination of a stellate cell-targeting
agent with gemcitabine and metformin was effective in tumors
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FIGURE 5 | Cell activation measurements. Human tumor-derived
pancreatic stellate cell migration was quantified and compared in cultures
isolated from patients with locally advanced, unresectable pancreatic
adenocarcinoma before treatment (Pre) and at 6 months following
treatment with gemcitabine (G) and stereotactic radiosurgery (SRS)
(Post). Box plots comparing (A) mean cell speed (micrometer per hour)
show no significant rate of change of position when traveling in culture.
(B)Total mean distance traveled (micrometer) is increased in human
tumor-derived pancreatic stellate cells post-treatment, and (C) expansion
and contraction ratio is higher in cells post-treatment. (D) Mean
expansion and contraction events and (E) directional change events per
cell showed no significant difference pre and post-treatment. Asterisks (*)
indicate statistically significant changes. *p<0.05, two-way ANOVA,
n=3 patients per cohort.
previously resistant to mTOR inhibition (23). These studies sug-
gest that targeting the tumor microenvironment could increase
susceptibility of CSCs to therapy and enhance the efficacy of
current treatments of PDAC.
Our study is the first report to evaluate stellate cells isolated
from FNAs of pancreatic tumors in patients. The restricted sup-
ply of fresh tumor tissue could be a limiting factor when studying
HTPSCs; our study provides a method for utilizing tissue obtained
from ultrasound-guided FNAs. Combining isolation of these cells
with single-cell tracking allowed us to study the behavior of these
cells in primary culture. This technique could be useful in assessing
the effect of other therapies on behavior of HTPSCs.
Earlier studies examined the effect of gemcitabine and radio-
therapy on PCCs using conditioned PSC media, irradiating
cells in culture, or by administering treatment to mice (6,
8, 33). Conditioned medium from cultured PSCs stimulated
pancreatic tumor cell proliferation, migration, invasion, and
anchorage-independent growth in a dose-dependent manner (6).
When irradiated PSCs were co-cultured with PCCs, PCCs had
increased clonogenic survival when cocultured with PSCs (8).
PSCs were exposed to gemcitabine in culture and were prac-
tically unaffected by the gradient doses of 5-fluorouracil or
gemcitabine (33).
Our study is the first to investigate HTPSCs after adminis-
tration of chemotherapy and radiation directly to humans with
PDAC. Using a novel single-cell tracking technology, we were
able to follow individual HTPSCs isolated from each patient
and quantify global changes of behavior after treatment. Our
findings revealed that HTPSCs survived treatment with gem-
citabine (G) plus concurrent hypo-fractionated SRS and had
altered behavior showing increased activation. HTPSCs isolated
from patients after treatment with G+ SRS traveled at the same
speed as cells isolated before treatment; however, they were more
motile, traveling 1.9 times further than untreated cells and had
greater membrane expansion ratios. The combination of increased
locomotion and membrane expansion in post-treatment cells
could possibly represent greater traction and increased intracel-
lular contractile force (41, 42). Cell migration and membrane
expansion/contraction are two markers of stellate cell activation;
(15) therefore, our data suggest that G+ SRS increases HTP-
SCs activation that could contribute to the tumor microenviron-
ment. Our studies further suggest that therapies to ablate stellate
cells should be used in conjunction with standard chemother-
apy and radiation to counteract the potential of these agents in
activation PSCs.
While our current study focuses on HTPSCs, the pancreatic
tumor microenvironment is a heterogeneous structure that also
includes CSCs, adipocytes, immune cells, endothelial cells, and
pericytes (28). The technique employed here focused on HTPSCs,
but it would be optimal to be able to analyze the global behavior
of the tumor microenvironment concurrently to determine cell
interaction and activation.
In summary, our findings reveal that HTPSCs can be success-
fully isolated from serial samples collected through ultrasound-
guided FNAs obtained from patients with locally advanced, unre-
sectable pancreatic adenocarcinoma. These cells survived in tis-
sues from patients orthotopically treated with gemcitabine and
hypo-fractionated SRS and displayed an activated phenotype with
increased cell migration and membrane expansion following treat-
ment. The ability to isolate these cells from patients undergoing
therapy and study their behavior in primary culture may help
our understanding of the pathophysiological role of this cell type
in pancreatic cancer and develop therapies that may be able to
specifically target these cells.
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